How Might Daratumumab Approval Influence Frontline Multiple Myeloma Care?
This main topic examines the potential impact of the approval of Daratumumab on front-line treatment for Multiple Myeloma.
FDA Issues Partial Clinical Hold on Lorigerlimab Trial in Gynecologic Cancers
A significant update: The FDA has put a partial clinical hold on the Lorigerlimab trial due to safety concerns.
Refining Management of Immune-Checkpoint Inhibitor Toxicities in Melanoma
This section focuses on the improvements being made in managing toxicities caused by Immune-Checkpoint inhibitors in treating melanoma.
FDA Grants Fast Track Designation to SRN-101 for Recurrent High-Grade Glioma
Another key development: The FDA has granted fast track designation to SRN-101 for the treatment of recurrent High-Grade Glioma.
Novel Small Molecule Shows Early Activity in Pretreated Multiple Myeloma
Positive outcomes have been observed from the application of a unique small molecule in treating Multiple Myeloma.
Comparing Quality of Life Outcomes with Protons vs Photons in OPSCC
This section makes a critical comparison between the quality of life outcomes when using Protons or Photons in treating OPSCC.
